Cookies are essential for the operation of our website. By using our website, you agree to the use of cookies. This website uses cookies to improve and personalize content, and for tracking and analytics. By clicking "Accept All Cookies", you are providing consent for Exelixis to collect and retain personal data for Exelixis to optimize the use of this website. You can learn more about Exelixis' use of cookies by reviewing Exelixis' Privacy Statement.
Phase 3 Study of Cabozantinib with Nivolumab and Ipilimumab vs Nivolumab and Ipilimumab Alone in Advanced Treatment-Naive Renal Cell Carcinoma


Thank you for your interest in the COSMIC Trials.

The COSMIC Trials are no longer recruiting

Phase 1b study of cabozantinib administered alone or in combination with atezolizumab for solid tumors

Learn More at Clinicaltrials.gov

Phase 3 pivotal trial of cabozantinib in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR (vascular endothelial growth factor receptor)–targeted therapy

Learn More at Clinicaltrials.gov

Phase 3 study of cabozantinib in combination with atezolizumab compared to sorafenib in advanced treatment-naive HCC (hepatocellular carcinoma)

Learn More at Clinicaltrials.gov

Phase 3 study of cabozantinib with nivolumab and ipilimumab vs nivolumab and ipilimumab alone in advanced treatment-naive RCC (renal cell carcinoma)

Learn More at Clinicaltrials.gov

USES DESCRIBED HERE ARE INVESTIGATIONAL.

SAFETY AND EFFICACY HAVE NOT BEEN ESTABLISHED.